Radiopharmaceuticals are an increasingly utilized therapeutic option for the treatment of malignancies. This session will focus on clinical indications, difficult cases, medical physics considerations, development of standard operating procedures for clinical implementation, billing and safe theranostic delivery practices. Specifically, Radium-223, Lutetium-177 dotatate and Lutetium-177 PSMA-617 will be discussed. The session will include didactic presentations from physician experts from radiation oncology, nuclear medicine, medical oncology and medical physicists, with question and answer sessions to discuss practice implementation in various clinical settings (i.e., academic hospital vs. community practice, nuclear medicine vs. radiation oncology). The purpose of the session is to increase physician, physicist and administration understanding on how to effectively and safely conduct a radiopharmaceutical program at their respective institutions.
